AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing ...
-AstraZeneca said it expected prescriptions of its COVID therapy to drive sales growth of more than 20% this year, as company ...
AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought by ...
May 28 (Reuters) - The U.S. Food and Drug Administration approved on Tuesday Amgen's (AMGN.O), opens new tab Bkemv, the first biosimilar to AstraZeneca's (AZN.L), opens new tab rare blood disorder ...